Validated markers of biologic activity for anti-angiogenic agents are not available and the assessment of clinically relevant and reproducible activity for these drugs is likely to be complex. Therefore, this application seeks to develop methods that will allow the diverse biologic processes contributing to angiogenesis to be assessed in patients. The long-term objective of this proposal will be to: develop reproducible methods to evaluate the molecular and cellular events that mediate anti-angiogenic effects in tumors and to use these methods to directly (analysis of tumor tissue) and indirectly (non-invasive imaging) evaluate anti-angiogenic treatment strategies in the clinic. Our primary focus will be to develop techniques to assess angiogenesis in patients using, 1. innovative immunohistochemical and biochemical tests developed in our laboratories and, 2. non-invasive imaging. To validate that these techniques can be applied to the clinical development of anti-angiogenic therapies, we will assess candidate biochemical assays and non-invasive techniques through the ongoing and proposed pre-clinical studies and clinical trials outlined in this proposal. We hypothesize that there are interim measures of anti-angiogenic activity that will enable early, accurate clinical assessment of anti-angiogenic therapies. To accomplish our long-term objective we propose a program of integrated Research Projects, Developmental Programs and Core Units with the following specific goals: (1) To clinically validate the relevance of putative surrogate markers of angiogenesis/anti-angiogenesis and the specific signaling pathways through which they control the expression of angiogenic proteins; (2) To clinically validate specific methods, developed in preclinical models, for detecting endothelial cell apoptosis in response by anti-angiogenic therapies; (3) To develop techniques to assess the molecular heterogeneity of tumor blood vessels, thereby improving our understanding of the biologic basis for responsiveness or resistance to anti-angiogenic therapies, and to use this information to develop noel targeted imaging strategies; (4) To develop and clinically validate non-invasive methods to assess the effectiveness of anti- angiogenic agents.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center--Cooperative Agreements (U54)
Project #
5U54CA090810-06
Application #
7054136
Study Section
Special Emphasis Panel (ZCA1-SRRB-D (J1))
Program Officer
Merritt, William D
Project Start
2001-07-16
Project End
2008-12-31
Budget Start
2006-09-05
Budget End
2008-12-31
Support Year
6
Fiscal Year
2006
Total Cost
$291,510
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Internal Medicine/Medicine
Type
Other Domestic Higher Education
DUNS #
800772139
City
Houston
State
TX
Country
United States
Zip Code
77030
Wang, Ruoning; Jung, Sung Yun; Wu, Chuan Fen et al. (2010) Direct roles of the signaling kinase RSK2 in Cdc25C activation during Xenopus oocyte maturation. Proc Natl Acad Sci U S A 107:19885-90
Kopetz, Scott; Hoff, Paulo M; Morris, Jeffrey S et al. (2010) Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance. J Clin Oncol 28:453-9
Connelly, Sarah F; Isley, Beth A; Baker, Cheryl H et al. (2010) Loss of tyrosine phosphatase-dependent inhibition promotes activation of tyrosine kinase c-Src in detached pancreatic cells. Mol Carcinog 49:1007-21
Trepel, Martin; Stoneham, Charlotte A; Eleftherohorinou, Hariklia et al. (2009) A heterotypic bystander effect for tumor cell killing after adeno-associated virus/phage-mediated, vascular-targeted suicide gene transfer. Mol Cancer Ther 8:2383-91
Ng, Chaan S; Kodama, Yoshihisa; Mullani, Nizar A et al. (2009) Tumor blood flow measured by perfusion computed tomography and 15O-labeled water positron emission tomography: a comparison study. J Comput Assist Tomogr 33:460-5
Wang, Wei; Shao, Ruping; Wu, Qingping et al. (2009) Targeting gelatinases with a near-infrared fluorescent cyclic His-Try-Gly-Phe peptide. Mol Imaging Biol 11:424-33
Kim, M P; Park, S I; Kopetz, S et al. (2009) Src family kinases as mediators of endothelial permeability: effects on inflammation and metastasis. Cell Tissue Res 335:249-59
Kopetz, Scott; Lesslie, Donald P; Dallas, Nikolas A et al. (2009) Synergistic activity of the SRC family kinase inhibitor dasatinib and oxaliplatin in colon carcinoma cells is mediated by oxidative stress. Cancer Res 69:3842-9
Nie, Jing; Chang, Benny; Traktuev, Dmitry O et al. (2008) IFATS collection: Combinatorial peptides identify alpha5beta1 integrin as a receptor for the matricellular protein SPARC on adipose stromal cells. Stem Cells 26:2735-45
Urbanczyk-Pearson, Lauren M; Femia, Frank J; Smith, Jeffrey et al. (2008) Mechanistic investigation of beta-galactosidase-activated MR contrast agents. Inorg Chem 47:56-68

Showing the most recent 10 out of 84 publications